Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series

Abstract

Abstract Our case series showed that eculizumab is efficacious and safe in treating thrombotic microangiopathy, as well as it has positive effects on quality of life. Further extensive studies are required to develop unified treatment guidelines.

Keywords

• atypical hemolytic uremic syndrome
• complement
• eculizumab
• nephrology
• thrombotic microangiopathy